UW-Madison researchers have developed a nanoparticle-based platform comprising targeting agents (i.e., tumor selective peptides) and active agents (e.g., immuno- and chemo-drugs).  The nanoparticles ...
Learn More

UW Madison researchers have provided herein biodegradable polymers and nanoparticles comprising such polymers. The present nanoparticles deliver antibiotics to infected tissue with enhanced antibacter...
Learn More

UW Madison researchers' present invention provides vectors for delivery of an anti-apoptotic therapy. The vectors include a phosphoglycerate kinase (Pgk) promoter operably connected to a polynucle...
Learn More

Biochemically active PASTA kinase inhibitors which exploit subtle structural differences between human kinases and bacterial PASTA kinases to improve specificity and inhibitor activity.
Learn More

The present invention from UW Madison researchers provides in vitro derived a multicell conjugate comprising an iNKT cell and a dendritic cell (DC). The invention also provides methods of making the m...
Learn More

The invention provides a vaccine comprising a recombinant biologically contained filovirus and methods of making and using those viruses.
Learn More

Ebola Virus Disease (EVD) is a severe and highly fatal hemorrhagic fever that affects humans and other mammals. It is caused by the Ebola virus, a single-stranded RNA virus that encodes seven structur...
Learn More

HERG-1 (human ether-a-go-go-related gene) potassium channels mediate repolarization of cardiac action potentials. Loss of function mutations in hERG-1 can result in long QT syndrome, an inherited diso...
Learn More

Every year worldwide, millions of people experience morbidity and mortality as a consequence of severe fungal disease. In the United States, mortality from invasive fungal disease is approximately 50 ...
Learn More

Currently there are no cell therapies approved for use against acute radiation injury (ARS). Severe ARS can cause death and the only cell treatment is allogenic bone marrow transplantation (BMT). Unfo...
Learn More

Most influenza vaccines are produced in embryonated chicken eggs, but increasingly influenza vaccines are produced in other systems. MDCK (Madin-Darby Canine Kidney) cells are one of two mammalian cel...
Learn More

Provided herein are polymer-drug conjugates with enhanced antibacterial efficacy. These conjugates include a polymer comprising a plurality of masked cationic functional groups and an antibiotic drug ...
Learn More

Provided herein are antigenic peptides comprising the SARS-CoV-2 spike protein receptor binding domain (CRBD) polypeptide or portions thereof, linked to a non-catalytic, non­toxic tetanus toxin varia...
Learn More

The present disclosure relates to vims-like particles and vaccine compositions for inducing immunity and preventing respiratory syncytial vims (RSV) infection. Specifically, the disclosure provides vi...
Learn More

A method to prepare recombinant influenza viruses comprising a mutant M2 protein which has a deletion of two or more residues in the cytoplasmic tail and is attenuated in vivo, is provided, as well th...
Learn More

An oral dosage form comprising a single dose of 25-hydroxy-vitamin D3 sufficient to elevate the serum level in a human to a concentration in the range of 30 ng/ml to 200 ng/ml for at least 7 days and ...
Learn More

This invention discloses 2-methylene-(20S,25R)-19,26-dinor-vitamin D analogs, and specifically 2-methylene-(20S,25R)-19,26-dinor-1α,25-dihydroxyvitamin D3, and pharmaceutical uses therefor. This comp...
Learn More

The present invention relates to methods of use of glycosyltransferases and related compounds. The invention exploits the reversibility of glycosyltransferases to generate new sugars, unnatural biomol...
Learn More

It is disclosed here a method for reducing phosphate absorption in a human or non-human animal subject wherein the subject consumes a diet containing phytic acid or phytate and either has or is at ris...
Learn More

A method for reducing phosphate absorption in a human or non-human animal subject at risk of developing or having developed hyperphosphatemia is disclosed. The method includes the step of administerin...
Learn More

This invention relates to vitamin D compounds, and more particularly to 2-methylene-1 α,25-dihydroxy-18,19,21-trinorvitamin D3 (DJ-55) and to pharmaceutical formulations that include this compound. T...
Learn More

This invention relates to vitamin D compounds, and more particularly to 2-methylene-1α-hydroxy-18,19,21-trinorvitamin D3 (SX-99) and to pharmaceutical formulations that include this compound. The inv...
Learn More

The invention provides 2-methylene-19-nor-(23R)-25-dehydro-1α-hydroxyvitamin D3-26,23-lactone (“GC-3”), 2-methylene-19-nor-(23S)-25-dehydro-1α-hydroxyvitamin D3-26,23-lactone (“HLV”), and re...
Learn More

This invention relates to vitamin D compounds, and more particularly to 19,26,27-trinor-1α,25-dihydroxyvitamin D3 compounds such as 2α-methyl-19,26,27-trinor-(20S)-1α,25-dihydroxyvitamin D3 (“P...
Learn More

The present invention uses pharmaceutical preparations of Botulinum toxin to induce neurogenic atrophy to alter muscle volume and subsequently, facial contour. Reduction in lip volume is accomplished ...
Learn More